Study on ALKAL1: A Potential Drug Target for Neurodegenerative Diseases
Study on ALKAL1: A Potential Drug Target for Neurodegenerative Diseases
ALKAL1 (AUGA) is a protein that is expressed in a variety of tissues throughout the body, including the brain, heart, liver, and kidneys. It is a member of the Tissue Response Proteins (TRPs) family, which are a group of proteins that are involved in various cellular processes in the body, including inflammation, stress, and repair.
One of the unique features of ALKAL1 is its ability to interact with other proteins that are expressed in the brain, including the neurotransmitter glutamate. Glutamic acid is an important neurotransmitter that can stimulate nerve cells and thereby transmit nerve signals. Under normal circumstances, glutamate is quickly broken down into glutamate, but under stress and disease conditions, glutamate may accumulate in nerve cells, causing nerve cell damage.
Therefore, it is very important to study the role of ALKAL1 in nerve cells. Scientists have discovered that ALKAL1 inhibits the effects of glutamate, thereby protecting nerve cells from damage. This provides new ideas for studying ALKAL1 as a therapeutic target for neurodegenerative diseases.
In addition, ALKAL1 interacts with many other proteins, including ligands of receptors on the cell membrane. These interactions allow ALKAL1 to participate in a variety of different biological processes, such as cell proliferation, apoptosis, cell signaling, and cell metabolism.
ALKAL1 is also closely related to the occurrence and development of some diseases. For example, ALKAL1 plays an important role in the pathogenesis of diseases such as Alzheimer's disease, Parkinson's disease, and liver disease. In these diseases, the role of glutamate and the function of ALKAL1 may be closely related to the occurrence and development of the disease.
Therefore, the potential role of ALKAL1 as a drug target or biomarker in neuroscience and disease treatment has received extensive research and attention. Future research will continue to deeply explore the function and mechanism of ALKAL1, providing new ideas and methods for neuroscience and disease treatment.
Protein Name: ALK And LTK Ligand 1
Functions: Cytokine that acts as a physiological ligand for receptor tyrosine kinase LTK, leading to its activation (PubMed:25331893, PubMed:26418745, PubMed:26630010, PubMed:34646012, PubMed:34819673). Monomeric ALKAL1 binds to LTK, leading to LTK homodimerization and activation (PubMed:34646012, PubMed:34819673). In contrast to ALKAL2, does not act as a potent physiological ligand for ALK (PubMed:26418745, PubMed:34646012)
More Common Targets
ALKAL2 | Alkaline Phosphatase (ALP) | ALKBH1 | ALKBH2 | ALKBH3 | ALKBH4 | ALKBH5 | ALKBH6 | ALKBH7 | ALKBH8 | ALLC | ALMS1 | ALMS1-IT1 | ALMS1P1 | ALOX12 | ALOX12-AS1 | ALOX12B | ALOX12P2 | ALOX15 | ALOX15B | ALOX15P1 | ALOX15P2 | ALOX5 | ALOX5AP | ALOXE3 | ALPG | Alpha-2 Adrenergic receptors | alpha-6 beta-2 Nicotinic receptor | alpha-Adrenoceptor | alpha-Amylase | alpha-beta T Cell Receptor Complex (TCR) | Alpha-crystallin | alpha-Mannosidase | alpha-Secretase | alpha1-Adrenoceptor | ALPI | ALPK1 | ALPK2 | ALPK3 | ALPL | ALPP | ALS2 | ALS2CL | ALX1 | ALX3 | ALX4 | ALYREF | AMACR | AMBN | AMBP | AMBRA1 | AMD1 | AMD1P2 | AMDHD1 | AMDHD2 | AMELX | AMELY | AMER1 | AMER2 | AMER3 | AMFR | AMH | AMHR2 | AMIGO1 | AMIGO2 | AMIGO3 | Amine oxidase (copper containing) | Amino acid hydroxylase | Aminoacyl-tRNA Synthetase Complex | AMMECR1 | AMMECR1L | AMN | AMN1 | AMOT | AMOTL1 | AMOTL2 | AMP Deaminase | AMP-activated protein kinase (AMPK) | AMP-activated protein kinase alpha1beta1gamma1 | AMP-activated protein kinase alpha2beta1gamma1 | AMP-activated protein kinase alpha2beta1gamma2 | AMP-activated protein kinase alpha2beta2gamma2 | AMPD1 | AMPD2 | AMPD3 | AMPH | AMT | AMTN | AMY1A | AMY1B | AMY1C | AMY2A | AMY2B | Amylin receptor | Amyloid beta A4 precursor protein-binding family (APP-BP) | AMZ1 | AMZ2 | AMZ2P1 | Anandamide membrane transporter (AMT) | ANAPC1